Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | ESR1 | P03372 | 4/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selenium SCHEMBL1402207 | 0.90 | TDP1 (0.92) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL457472 | 0.88 | CYP3A4 (0.67) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL101 | 0.87 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL5028587 | 0.87 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL2085135 | 0.87 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2KDM4E | |
| Benzene SCHEMBL6890099 | 0.87 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL21296017 | 0.84 | TDP1 (0.80) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL21296015 | 0.84 | TDP1 (0.80) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL11498882 | 0.84 | TDP1 (0.80) | CYP3A4TDP1ESR1ESR2KDM4E | |
| Iodomethane SCHEMBL114985 | 0.84 | TDP1 (0.80) | CYP3A4TDP1ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827257-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2017-11-28 | — | — | US | disclosed |
| US-9750759-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2017-09-05 | — | — | US | disclosed |
| EP-2597091-B1 | Antitumoral Compounds | PHARMA MAR SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-20150344454-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2015-12-03 | — | — | US | disclosed |
| US-20150342972-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2015-12-03 | — | — | US | disclosed |
| US-9187445-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2015-11-17 | — | — | US | disclosed |
| US-8710264-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-04-29 | — | — | US | disclosed |
| EP-2231633-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-10-30 | — | — | EP | disclosed |
| US-8501968-B2 | Antitumoral dihydropyran-2-one compounds | PHARMAMAR, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| EP-2597091-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2013-05-29 | — | — | EP | disclosed |
| US-20110034549-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2011-02-10 | — | — | US | disclosed |
| US-20100280108-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-04 | — | — | US | disclosed |
| EP-2231633-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231590-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-23 | — | — | US | disclosed |
| WO-2009080761-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080769-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| EP-2032551-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344454-A1 | ANTITUMORAL COMPOUNDS | TP53, CCNY, RB1 | CYP3A4 1645/4885TDP1 2183/4885ESR1 1130/4885 |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | CYP3A4 2461/4885TDP1 2575/4885ESR1 4404/4885 |
| US-20150342972-A1 | ANTITUMORAL COMPOUNDS | TP53, CCNY, RB1 | CYP3A4 1645/4885TDP1 2183/4885ESR1 1130/4885 |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | CYP3A4 2461/4885TDP1 2575/4885ESR1 4404/4885 |
| US-20100280108-A1 | Antitumoral Compounds | TPD52L2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53 | CYP3A4 1244/4885TDP1 2238/4885ESR1 1263/4885 |
| US-20110034549-A1 | Antitumoral Compounds | CCNY, RB1, TPD52L2 | CYP3A4 2182/4885TDP1 2148/4885ESR1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.